AstraZeneca's diabetes drug Farxiga helps patients with heart disease and without...

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Aug 20, 2019 at 10:32 AM.

  1. #1 cafead, Aug 20, 2019 at 10:32 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,046
    Likes Received:
    3
    via Months ago, data on J&J’s $JNJ Invokana indicated the diabetes drug conferred cardiovascular (CV) benefit in patients who do and do not have preexisting CV disease. On Tuesday, AstraZeneca’s $AZN rival treatment, Farxiga, was shown to cut the risk of CV death or the worsening of heart failure in patients with heart disease, in a landmark trial.

    article source
     
    Quote

Reply to Thread